Horizon Therapeutics has teamed up with Xeris Biopharma to create an ultra-concentrated, ready-to-use, subcutaneous formulation of teprotumumab, handing over an upfront payment and offering milestones to get its new partner to apply XeriJect to the molecule.
Teprotumumab, an anti-IGF-1R blocking antibody, came to market in 2020 as a treatment for the rare condition thyroid eye disease. The molecule, which Horizon sells as Tepezza, is given as an intravenous infusion. Patients receive eight infusions with three-week gaps between sessions. The first two infusions take about 90 minutes. The remaining six last around 60 minutes, although they can be longer.
The intravenous dosing schedule suggests a subcutaneous formulation may significantly reduce the time people spend getting treated, lifting a burden from patients and potentially improving adherence. Even relatively large volume subcutaneous drugs are typically administered in five minutes or less.
Xeris will use XeriJect to try to develop a subcutaneous formulation of teprotumumab. Using drying or particle engineering techniques, Xeris creates powders ready for “wetting” with biocompatible diluents. The process yields ultra-concentrated, low-volume paste formulations suitable for subcutaneous or intravenous delivery. Xeris has formulated suspensions with protein concentrations of 400 mg/mL or more.